Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancers
NCT04910386Phase 2Not yet recruiting
- Sponsor
- 3D Medicines Inc.
- Start
- Jun 2027
- Primary completion
- Jun 2029
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of envafolimab in biliary tract cancer (BTC) (2 arms), sponsored by 3D Medicines Inc. Primary endpoint: Progression-Free Survival at 12 weeks. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04910386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910386.